StockData

ProPhase Labs, Inc. (PRPH) stock

PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 0/30
$0.01−0.00 (-6.16%)

Close on Oct 19, 2026Market cap $119.68KP/E –Yield –

ProPhase Labs ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

ProPhase Labs's ebitda for the twelve months ending Jun 30, 2026 was -$12.32M. For fiscal 2025 it was -$13.22M. The highest annual figure on record is $28.31M in fiscal 2022.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.22M–
FY2024Dec 31, 2024-$32.44M–
FY2023Dec 31, 2023-$15.17M-153.6%
FY2022Dec 31, 2022$28.31M+117.2%
FY2021Dec 31, 2021$13.04M–
FY2020Dec 31, 2020-$1.63M–
FY2019Dec 31, 2019-$2.84M–
FY2018Dec 31, 2018-$1.25M–
FY2017Dec 31, 2017-$3.65M–
FY2016Dec 31, 2016-$2.23M–
FY2015Dec 31, 2015-$3.22M–
FY2014Dec 31, 2014-$7.55M-1245.8%
FY2013Dec 31, 2013$659.00K–
FY2012Dec 31, 2012-$846.00K–
FY2011Dec 31, 2011-$2.38M–
FY2010Dec 31, 2010-$3.23M–
FY2009Dec 31, 2009-$3.41M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.02M–
Q1 FY2026Mar 31, 2026-$1.46M–
Q4 FY2025Dec 31, 2025-$4.76M–
Q3 FY2025Sep 30, 2025-$4.07M–
Q2 FY2025Jun 30, 2025-$2.88M–
Q1 FY2025Mar 31, 2025-$2.18M–
Q4 FY2024Dec 31, 2024-$15.77M–
Q3 FY2024Sep 30, 2024-$4.95M–
Q2 FY2024Jun 30, 2024-$5.70M–
Q1 FY2024Mar 31, 2024-$6.03M-378.1%
Q4 FY2023Dec 31, 2023-$9.34M–
Q3 FY2023Sep 30, 2023-$3.91M-231.5%
Q2 FY2023Jun 30, 2023-$4.14M-135.1%
Q1 FY2023Mar 31, 2023$2.17M-87.5%
Q4 FY2022Dec 31, 2022-$4.16M-128.0%
Q3 FY2022Sep 30, 2022$2.97M–
Q2 FY2022Jun 30, 2022$11.78M–
Q1 FY2022Mar 31, 2022$17.40M+890.0%
Q4 FY2021Dec 31, 2021$14.87M–
Q3 FY2021Sep 30, 2021-$3.25M–
Q2 FY2021Jun 30, 2021-$1.06M-1748.4%
Q1 FY2021Mar 31, 2021$1.76M–
Q4 FY2020Dec 31, 2020-$565.00K–
Q3 FY2020Sep 30, 2020-$564.00K–
Q2 FY2020Jun 30, 2020$64.00K–
Q1 FY2020Mar 31, 2020-$730.00K–
Q4 FY2019Dec 31, 2019-$370.00K–
Q3 FY2019Sep 30, 2019-$361.00K–
Q2 FY2019Jun 30, 2019-$1.17M–
Q1 FY2019Mar 31, 2019-$943.00K-2345.2%
Q4 FY2018Dec 31, 2018-$310.00K–
Q3 FY2018Sep 30, 2018-$815.00K–
Q2 FY2018Jun 30, 2018-$169.00K–
Q1 FY2018Mar 31, 2018$42.00K–
Q4 FY2017Dec 31, 2017-$520.00K-159.8%
Q3 FY2017Sep 30, 2017-$796.00K–
Q2 FY2017Jun 30, 2017-$790.00K–
Q1 FY2017Mar 31, 2017-$422.00K–
Q4 FY2016Dec 31, 2016$870.00K–
Q3 FY2016Sep 30, 2016-$682.00K–

More ProPhase Labs figures

See a number that looks wrong?